GlassScriptPhysician profile
Neda Danniel
NPI 1588221758
$4,018.84
in general payments reported to CMS, 2019-2025
36 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.07 · 2023: $1,709 · 2024: $1,606 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,920.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,369.10 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $415.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $210.99 | 2023-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Lilly USA, LLC | $182.44 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $154.17 | 2023-2025 | Evenity, Prolia, Otezla |
| Gilead Sciences, INC. | $151.36 | 2023-2024 | Veklury |
| Radius Health, INC. | $134.04 | 2023-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $128.66 | 2023-2024 | Xarelto |
| Astellas Pharma US INC | $123.01 | 2023-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $114.62 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $93.84 | 2023-2025 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.54 | 2023-2024 | Xifaxan |
| Eisai INC. | $82.17 | 2023-2024 | |
| Exact Sciences Corporation | $76.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neda Danniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.